- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01866449
Prospective Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme
Prospective Controlled Phase 2 Trial of Cabazitaxel in Patients With Temozolomide Refractory Glioblastoma Multiforme (GBM)- The C-GBM Study -
The proposed study is an open-label, single-arm, Phase- II trial to assess the efficacy of cabazitaxel in GBM WHO grade IV patients with a progression during or within 6 months after last temozolomide treatment (Figure 1).
Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks with standard concomitant medication (as outlined below):
- On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25mg/m², administered by i.v. route in 1 hour.
- Cycle length for cabazitaxel is 3 weeks (21 days).
- New cycles of therapy may not begin until Absolute Neutrophil Count (ANC) ≥1500/mm3, platelet count ≥75 000/mm3, and non-hematological toxicities (except alopecia) have recovered to baseline.
- A maximum of 2 weeks (14 days) delay is allowed between 2 treatment cycles.
- Patients should come off treatment if treatment delay is more than 2 weeks.
At least 30 minutes prior to each administration of cabazitaxel, patients will receive i.v. premedication including:
- An antihistamine (dexchlorpheniramine 5mg, diphenhydramine 25mg, or equivalent). In case of i.v. antihistamine other than promethazine is not being available, local practice should be followed.
- Corticosteroid (dexamethasone 8mg or equivalent)
- H2 antagonist (ranitidine or equivalent).
- Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary.
- Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) should be given on day 4 of each treatment cycle as per ASCO and ESMO guidelines.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Augsburg, Germany, 86150
- Hämatologisch onkologische Praxis
-
Koblenz, Germany, 56068
- Stiftungsklinikum Mittelrhein GmbH
-
Ulm, Germany, 89081
- Lars Bullinger, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Both female and male patients meeting the mentioned inclusion and exclusion criteria will be included in this clinical trial. Patients must meet ALL of the following inclusion criteria to be eligible for enrollment into the study:
- Patients with diagnosis glioblastoma multiforme (GBM) WHO grade IV (histologically confirmed by a pathologist)
- Progression during or within 6 months after last temozolomide treatment
- Time since last temozolomide > 21 days
- Prior external beam radiotherapy (54 to 62 Gy), no option for subsequent radiotherapy
- No clinical and radiological signs of intracerebral inflammation (in pre-study MRI not older than 4 weeks)
- Patients > 18 years of age.
- ECOG performance status of ≤ 2 (stable over 4 weeks prior to study entrance)
- Female patients of childbearing potential with a negative pregnancy test within 7 days of initiation of study treatment. Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.
- Male and female patients of reproductive potential who agree to employ an effective method of birth control throughout the study and for up to 6 months following discontinuation of study drug.
- Signed informed consent prior to initiation of any study procedure (Must understand, voluntarily sign the informed consent form and be able to adhere to the study visit schedule and other protocol requirements.)
Exclusion Criteria:
The presence of ANY of the following criteria will exclude a patient from study enrollment:
- Female patients who are pregnant or breast-feeding
- History of severe hypersensitivity reaction (≥grade 3) to any component of the investigational drugs or excipients (allergy to or other intolerability of gadolinium, docetaxel, cabazitaxel or polysorbate 80 containing drugs)
- Unable to undergo Gd-MRI
- Time since external beam radiotherapy <12 weeks
- Patients who have been treated with any investigational agent(s) within 28 days of the first day of administration of study drug.
- Current active second malignancy other than non-melanoma skin cancers and post-treatment of localized prostate cancer. Patients are not considered to have a currently active malignancy if they are in complete remission for > 3 years prior to study
- Uncontrolled severe illness or medical condition (including uncontrolled diabetes mellitus)
- Known HIV infection, active Hepatitis B or C infection
- Any serious and/or unstable pre-existing psychiatric or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures
- Any ongoing toxicity from prior anti-cancer therapy that is > grade 1 and/or that is progressing in severity (except alopecia) and delayed hematological recovery following last temozolomide cycle
- Additional anti-cancer treatment for GBM other than study drug and supportive measures (i.e. dexamethasone)
Inadequate organ and bone marrow function as evidenced by:
- Hemoglobin <9.0 g/dL
- Absolute neutrophil count <1.5 x 109/L,
- Platelet count <100 x 109/L,
- AST/SGOT and/or ALT/SGPT >1.5 x ULN;
- Total bilirubin >1.0 x ULN,
- Serum creatinine >1.5 x ULN. If creatinine 1.0 - 1.5 x ULN, creatinine clearance will be calculated according to CKD-EPI formula and patients with creatinine clearance <60 mL/min should be excluded
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cabazitaxel
Cabazitaxel will be given at a dose of 25mg/m² as 1h infusion every 3 weeks
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response including SD, PR or CR determined by MRI (modified RANO criteria)
Time Frame: 1 year
|
• Response after 12 weeks
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall and progression-free survival
Time Frame: 3 years
|
3 years
|
|
Safety and tolerability
Time Frame: 3 years
|
|
3 years
|
Pharmacokinetics data concerning drug interactions (i.e. CYP3A induction)
Time Frame: 3 years
|
Pharmacokinetics of cabazitaxel in patients with and without concomitant anticonvulsive medication with respect to induction of CYP3A
|
3 years
|
Quality of life and neurocognitive functioning
Time Frame: 3 years
|
Assessment of quality of life, determined by assessment with EORTC QLQ questionnaires (C30 and BN20), and neurocognitive functioning, determined by repeated standardized measurements using MMSE
|
3 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- C-GBM (XRP6258)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glioblastoma Multiforme (GBM) WHO Grade IV
-
Children's Hospital Medical Center, CincinnatiTerminatedGlioblastoma Multiforme (WHO Grade IV) | Anaplastic Astrocytoma (WHO Grade III)United States
-
Patrick Wen, MDBristol-Myers SquibbActive, not recruitingGlioblastoma | Glioblastoma Multiforme | GBM | Grade IV AstrocytomaUnited States
-
Beijing Tiantan HospitalZhongSheng BioTech Inc.RecruitingWHO Grade III Gliomas | WHO Grade IV GliomasChina
-
University of FloridaNational Cancer Institute (NCI)CompletedGlioblastoma | Glioblastoma Multiforme | Malignant Glioma | GBM | Astrocytoma, Grade IVUnited States
-
Northwell HealthCompletedGBM | Anaplastic Astrocytoma | Glioblastoma Multiforme (GBM) | ANAPLASTIC ASTROCYTOMA (AOA)United States
-
TVAX BiomedicalCompletedGlioblastoma Multiforme | Grade IV Astrocytoma | Grade IV GliomaUnited States
-
Medicenna Therapeutics, Inc.CompletedGlioblastoma | Glioblastoma Multiforme | Grade IV Astrocytoma | Grade IV GliomaUnited States
-
Nationwide Children's HospitalNovartisNot yet recruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV GliomaUnited States, Australia, United Kingdom, Canada, Germany, Netherlands
-
Nationwide Children's HospitalNot yet recruitingGlioblastoma | Glioblastoma Multiforme | High Grade Glioma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine Glioma | Diffuse Midline Glioma, H3 K27M-Mutant | WHO Grade III Glioma | Metastatic Brain Tumor | WHO Grade IV GliomaUnited States, Australia, United Kingdom, Canada, Germany, Netherlands
-
University of UtahWithdrawnGlioblastoma Multiforme (GBM)United States
Clinical Trials on Cabazitaxel
-
Jeffrey Yachnin M.D., PhD.SanofiCompletedMetastatic Castration Resistant Prostate CancerSweden
-
Krzysztof MisiukiewiczSanofi; Icahn School of Medicine at Mount SinaiCompleted
-
Vejle HospitalSanofiTerminated
-
Azienda Socio Sanitaria Territoriale degli Spedali...San Luigi Gonzaga HospitalUnknown
-
Institut für Klinische Krebsforschung IKF GmbH...Completed
-
Gustave Roussy, Cancer Campus, Grand ParisSanofiUnknownNon-seminomatous Germ-cell TumorsFrance
-
Rambam Health Care CampusCompleted
-
University Hospitals Bristol and Weston NHS Foundation...SanofiCompletedPenile NeoplasmUnited Kingdom
-
Brown UniversityTerminated
-
European Organisation for Research and Treatment...SanofiCompletedDedifferentiated LiposarcomaUnited Kingdom, Belgium, France, Italy